Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accumulated Depreciation (2018 - 2025)

Fortress Biotech (FBIO) has 11 years of Accumulated Depreciation data on record, last reported at $2.9 million in Q3 2025.

  • For Q3 2025, Accumulated Depreciation fell 75.96% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $2.9 million, down 75.96%, while the annual FY2024 figure was $9.9 million, 11.7% up from the prior year.
  • Accumulated Depreciation reached $2.9 million in Q3 2025 per FBIO's latest filing, up from $2.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $13.3 million in Q1 2023 and bottomed at $2.7 million in Q1 2025.
  • Average Accumulated Depreciation over 5 years is $9.0 million, with a median of $9.3 million recorded in 2021.
  • Peak YoY movement for Accumulated Depreciation: skyrocketed 40.53% in 2024, then tumbled 75.96% in 2025.
  • A 5-year view of Accumulated Depreciation shows it stood at $9.4 million in 2021, then soared by 32.49% to $12.4 million in 2022, then decreased by 28.56% to $8.9 million in 2023, then rose by 11.7% to $9.9 million in 2024, then plummeted by 71.04% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation were $2.9 million in Q3 2025, $2.7 million in Q1 2025, and $9.9 million in Q4 2024.